Oppenheimer Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $540
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Vertex Pharmaceuticals but lowers the price target from $550 to $540.

October 30, 2024 | 4:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer's analyst Hartaj Singh continues to rate Vertex Pharmaceuticals as Outperform, but has slightly reduced the price target from $550 to $540.
The Outperform rating suggests continued confidence in Vertex Pharmaceuticals' performance, but the slight reduction in the price target indicates a minor adjustment in expectations. This is likely to have a neutral short-term impact on the stock price as the overall positive outlook remains unchanged.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100